All productsSS-31
Size
- 10 mg — $40.00 CAD — Available
Research focus
Elamipretide has been studied in mitochondrial disease, including controlled trials measuring walking and fatigue.
In simple words
SS-31, also called elamipretide, is a peptide investigated in conditions affecting mitochondria and cellular energy systems. The selected clinical study measured walking and fatigue in a specific disease population, not general wellness.
SS-31 is commonly called elamipretide. Evidence from a specific disease population does not establish general wellness effects.
Research references
Reviewed 2026-10-26
Human — randomized phase 3 trial
218 people with genetically confirmed primary mitochondrial myopathy.
The trial did not meet its primary endpoints: walking distance and fatigue were not improved compared with placebo at 24 weeks.
Most reported adverse events were mild to moderate. Findings concern this disease population and do not support general energy or anti-ageing promises.
PMID 37268435. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about SS-31
What is SS-31?
SS-31, also called elamipretide, is a peptide investigated in conditions affecting mitochondria and cellular energy systems. The selected clinical study measured walking and fatigue in a specific disease population, not general wellness.
What types of research are cited for SS-31?
The SS-31 profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Elamipretide: MMPOWER-3 (2023): Human — randomized phase 3 trial
Publication: Elamipretide: MMPOWER-3Who or what was studied in the selected SS-31 references?
Elamipretide: MMPOWER-3 (2023): 218 people with genetically confirmed primary mitochondrial myopathy.
Publication: Elamipretide: MMPOWER-3What identity distinctions matter for SS-31?
SS-31 is commonly called elamipretide. Evidence from a specific disease population does not establish general wellness effects.
What do the selected SS-31 studies not establish?
Elamipretide: MMPOWER-3 (2023): Most reported adverse events were mild to moderate. Findings concern this disease population and do not support general energy or anti-ageing promises.
Publication: Elamipretide: MMPOWER-3These studies do not establish the identity, purity, safety or effects of the MXC SS-31 vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.